Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neovascular (Wet) Age-related Macular Degeneration (nAMD)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 15 of 0 results

Not applicableWithdrawnNCT06398080
What this trial is testing

An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting

Who this might be right for
Neovascular Age-related Macular Degeneration (nAMD)Wet Age-related Macular Degeneration (AMD)Diabetic Macular Edema (DME)+1 more
Regeneron Pharmaceuticals
Early research (Phase 1)Study completedNCT04635800
What this trial is testing

Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients

Who this might be right for
Macular EdemaDiabetic Macular EdemaNeovascular Age-related Macular Degeneration+1 more
Novartis Pharmaceuticals 21
Post-approval studies (Phase 4)Ended earlyNCT05473715
What this trial is testing

Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment

Who this might be right for
Neovascular (Wet) Age-related Macular Degeneration
Bayer 3
Not applicableNot Yet RecruitingNCT07744204
What this trial is testing

LEAP Strategy for Neovascular Age-Related Macular Degeneration

Who this might be right for
Neovascular Age-related Macular Degeneration(nAMD)Wet Macular Degeneration
Chinese PLA General Hospital 240
Large-scale testing (Phase 3)Looking for participantsNCT07482176
What this trial is testing

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc. 534
Not applicableStudy completedNCT04847895
What this trial is testing

Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications

Who this might be right for
Neovascular (Wet) Age-related Macular Degeneration
Novartis Pharmaceuticals 5,500
Large-scale testing (Phase 3)Study completedNCT03823300
What this trial is testing

Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

Who this might be right for
Wet Macular Degeneration
Hoffmann-La Roche 658
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07798375
What this trial is testing

Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration

Who this might be right for
Neovascular Age Related Macular Degeneration(nAMD)
Everest Medicines (China) Co.,Ltd. 244
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07178249
What this trial is testing

Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD

Who this might be right for
Wet Age-related Macular Degeneration
Guangzhou Jiayin Biotech Ltd 60
Post-approval studies (Phase 4)Study completedNCT01775124
What this trial is testing

Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 332
Testing effectiveness (Phase 2)Study completedNCT04832724
What this trial is testing

RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-related Macular DegenerationWet Macular DegenerationWet Age-related Macular Degeneration
AbbVie 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT04514653
What this trial is testing

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)
AbbVie 146
Testing effectiveness (Phase 2)Study completedNCT03066258
What this trial is testing

Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial

Who this might be right for
Neovascular Age-related Macular DegenerationWet Age-related Macular Degeneration
REGENXBIO Inc. 42
Testing effectiveness (Phase 2)Study completedNCT03927690
What this trial is testing

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

Who this might be right for
Diabetic Macular Edema
Novartis Pharmaceuticals 91
Not applicableStudy completedNCT07744984
What this trial is testing

The Efficacy of Home OCT Supported Management in Patients Diagnosed With Neovascular-AMD and Undergoing a Drug Switch to Faricimab

Who this might be right for
Age-Related Macular Degeneration (AMD)Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Rabin Medical Center 12